PAH Pathways^® is there every step of the way

Your one point of contact for Actelion services and support

	Simplifies enrollment process for expedited access to Tracleer
	A clear path to reimbursement information and financial assistance programs*
	Unique online patient management with PATHwatch™ and LabTrac™
	Extensive patient education and support with Sure Steps™

*For eligible patients.

PAH Pathways counselors

PAH Pathways counselors will help clarify insurance issues to expedite Tracleer initiation and determine financial assistance program eligibility.

For more information, please visit www.PAHPathways.com.


PATHwatch online patient management: With our online patient management program, you can save time and paperwork by gaining secure and instant information about your patients enrolled in the Tracleer Access Program (T.A.P.^®).

Register today and start saving time and paperwork: Call, toll-free, 1-866-ACTELION (1-866-228-3546) or click here to download the PATHwatch registration form and fax to: 1-866-279-0669. Your username and password will arrive via secure delivery in 3 to 5 business days. Already a member? Click here.


LabTrac: A simple way to track lab results for your patients enrolled in the Tracleer Access Program (T.A.P.^®). LabTrac, a program in which you might be participating, allows for the easy review of information for your patients taking Tracleer. If you are currently enrolled in LabTrac, visit www.LabTrac.info.

If you are interested in participating, please contact your Actelion representative.


Sure Steps: Complements your efforts in educating your Tracleer patients—providing them with information to help manage their disease. Sure Steps is available at no cost to all patients who are taking Tracleer for WHO Class II-IV PAH.

For more information, please call 1-866-ACTELION (1-866-228-3546) or click here.

Tracleer is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in patients with WHO Class II-IV symptoms, to improve exercise ability and decrease the rate of clinical worsening. Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these potential benefits are sufficient to offset liver injury in WHO Class II patients, which may preclude future use as their disease progresses.

Important safety information

Because of the associated risks, Tracleer may be prescribed only through the Tracleer Access Program.

Potential for serious liver injury (including, after prolonged treatment, rare cases of liver failure and unexplained hepatic cirrhosis in a setting of close monitoring)—Liver monitoring of all patients is essential prior to initiation of treatment and monthly thereafter.

High potential for major birth defects—Pregnancy must be excluded and prevented through the use of reliable forms of birth control; monthly pregnancy tests should be obtained.

Contraindicated for use with cyclosporine A and glyburide.

Please see full prescribing information including BOXED WARNING.

Read about Tracleer Managed Care / Access